Dana-Farber Cancer Institute: Neoplasm Metastasis trials

The registry lists 13 Neoplasm Metastasis studies with Dana-Farber Cancer Institute as lead sponsor. 0 are open to participants now and 4 have results posted.

Phase 1 5Phase 2 8No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms TumorsTerminatedNCT02581384Phase 1/2Results posted
• Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain MetastasesCompletedNCT02260531Phase 2Results posted
• Fulvestrant With or Without Ganetespib in HR+ Breast CancerCompletedNCT01560416Phase 2Results posted
• Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric CancerCompletedNCT00130689Phase 2Results posted
• Axillary Lymph Node Tattoo Marking StudyTerminatedNCT04947917Not applicable
• A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid TumorsCompletedNCT02133625Phase 1
• ARRY-380 + Trastuzuamab for Breast w/ Brain MetsCompletedNCT01921335Phase 1
• Dendritic Cell Activating Scaffold in MelanomaCompletedNCT01753089Phase 1
• BKM120+Abiraterone Acetate for Metastatic CRPCTerminatedNCT01741753Phase 1
• Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal CancerCompletedNCT00165568Phase 2
• Tarceva and Capecitabine for Pancreatic CancerCompletedNCT00125021Phase 2
• Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal CancerCompletedNCT00123851Phase 2
• Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal CancerCompletedNCT00116506Phase 2